Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian acquired 22,807 shares of common stock through a compensation-related grant. The shares are represented by performance share units (PSUs) that were awarded upon achievement of specified performance metrics and vested on August 18, 2026. Following this vesting, Bedrosian holds 288,092 common shares directly.

Insider Trade Summary

Net Buyer: 22,807 shares

Net Buy 1 txn

Insider Bedrosian Camille L

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	22,807	$0.00	$0.00

Holdings After Transaction: Common Stock — 288,092 shares (Direct)

Footnotes (1)

1. F1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

Key Figures

Shares acquired: 22,807 shares of Common Stock Transaction price per share: $0.00 per share Shares owned after transaction: 288,092 shares of Common Stock +2 more

5 metrics

Shares acquired 22,807 shares of Common Stock Grant, award, or other acquisition of non-derivative securities on August 18, 2026

Transaction price per share $0.00 per share Reported for the 22,807-share compensation award

Shares owned after transaction 288,092 shares of Common Stock Direct ownership following the PSU vesting transaction

Transaction code Code A Indicates a grant, award, or other acquisition of securities

Security title Common Stock Non-derivative security received upon PSU vesting

Key Terms

performance share units, PSUs, vested, Grant, award, or other acquisition

4 terms

performance share units financial

"The reported shares are represented by performance share units, or PSUs, and were awarded"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

PSUs financial

"represented by performance share units, or PSUs, and were awarded upon the achievement"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

vested financial

"Shares subject to the PSU vested on August 18, 2026."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

FAQ

What insider transaction did AMLX report for Camille L. Bedrosian?

Amylyx Pharmaceuticals reported that Chief Medical Officer Camille L. Bedrosian received a grant of 22,807 shares of common stock represented by performance share units, which vested on August 18, 2026, increasing her direct holdings to 288,092 shares.

Was the AMLX insider transaction a market purchase or a compensation award?

The transaction was a compensation-related award, coded as a grant or other acquisition. The 22,807 shares were delivered at a reported price of $0.00 per share, consistent with vesting of performance share units rather than a market purchase.

What are performance share units (PSUs) in the AMLX Form 4 filing?

The filing states that the reported shares are represented by performance share units (PSUs) that were awarded upon the achievement of certain performance metrics, and that the shares subject to the PSU vested on August 18, 2026.

How many AMLX shares does Camille L. Bedrosian own after this transaction?

After the reported award and vesting of 22,807 shares, Chief Medical Officer Camille L. Bedrosian directly holds 288,092 shares of Amylyx Pharmaceuticals common stock, according to the Form 4 disclosure.

Does the AMLX Form 4 indicate any insider sales by Camille L. Bedrosian?

No insider sales are reported. The Form 4 shows one compensation-related acquisition of 22,807 shares through vested performance share units, with no sale transactions listed for Camille L. Bedrosian.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 09:00 PM Accepted by SEC EDGAR 08/20/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bedrosian Camille L

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		A		22,807(1)	A	$0	288,092	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

	/s/ Joshua B. Cohen, as Attorney in Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)